Form 4: Monopar Therapeutics COO Andrew Cittadine Boosts Direct Stock Holdings Through RSU Vesting

Monopar Therapeutics' Chief Operating Officer, Andrew Cittadine, increased his direct beneficial ownership of common stock to 45,858 shares following the vesting of restricted stock units on June 30, 2025.

Summary

• Andrew Cittadine, Chief Operating Officer of Monopar Therapeutics (MNPR), reported changes in his beneficial ownership of company common stock.
• On June 30, 2025, Cittadine acquired 6,863 shares of common stock through the vesting and settlement of restricted stock units.
• Concurrently, 2,990 shares were disposed of at a price of $35.78 per share to cover applicable withholding taxes related to the RSU vesting.
• Following these transactions, Cittadine's direct beneficial ownership of Monopar Therapeutics common stock stands at 45,858 shares.
• He also holds 43,001 restricted stock units that are yet to vest, with various vesting schedules extending to December 2028.

Sentiment

Score: 7

Explanation: The filing indicates a routine insider transaction where an executive's equity holdings increased through RSU vesting, which is generally a positive sign of alignment with shareholder interests, despite a portion being sold for tax purposes. It's a standard compensation event.

Positives

• Chief Operating Officer Andrew Cittadine increased his direct beneficial ownership of Monopar Therapeutics common stock by a net of 3,873 shares (6,863 acquired minus 2,990 withheld for taxes) on June 30, 2025.
• The acquisition of shares through RSU vesting indicates the fulfillment of long-term incentive compensation, aligning management interests with shareholder value.

Negatives

• A portion of the vested shares, specifically 2,990 shares, were sold at $35.78 per share to cover tax obligations, which represents a reduction in the total shares acquired from vesting.

Risks

• The value of the common stock and remaining restricted stock units is subject to market fluctuations inherent in equity investments.
• Future vesting of restricted stock units is contingent on continued employment and company performance, as per the terms of the RSU grants.

Future Outlook

Andrew Cittadine holds 43,001 unvested restricted stock units, with vesting schedules extending until December 31, 2025, for the February 2, 2022 grant; until December 31, 2026, for the February 1, 2023 grant; and until December 31, 2028, for the March 4, 2025 grant. These future vestings represent potential increases in his common stock holdings.

Industry Context

This Form 4 filing reflects routine equity compensation practices common across publicly traded companies, particularly in the biotechnology or pharmaceutical sector like Monopar Therapeutics, where long-term incentives such as restricted stock units are used to align executive interests with shareholder value and retain key talent.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of executive compensation is a standard practice across various industries, including biotechnology, aligning executive incentives with long-term company performance.
• The practice of withholding shares to cover tax obligations upon RSU vesting is also a common and standard procedure for equity compensation plans, ensuring tax compliance for the recipient and the issuer.
• The vesting schedules, typically over several years, are consistent with industry norms for retaining executives and incentivizing sustained performance.

Stakeholder Impact

• Shareholders: The increase in direct beneficial ownership by a key executive like the COO can be viewed positively, signaling management's continued vested interest in the company's performance. The RSU vesting mechanism aligns executive incentives with long-term shareholder value.
• Employees: The RSU grants and vesting demonstrate the company's commitment to long-term equity compensation, which can be a positive signal for employee retention and motivation, particularly for key personnel.

Next Steps

• Continued vesting of Andrew Cittadine's remaining 43,001 restricted stock units according to their respective schedules until December 31, 2025, December 31, 2026, and December 31, 2028.

Key Dates

Keywords

Monopar Therapeutics, MNPR, Andrew Cittadine, Chief Operating Officer, COO, SEC Form 4, insider transaction, stock ownership, restricted stock units, RSU vesting, common stock, beneficial ownership, equity compensation, tax withholding